275 related articles for article (PubMed ID: 30999933)
1. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
Winthrop KL; Bingham CO; Komocsar WJ; Bradley J; Issa M; Klar R; Kartman CE
Arthritis Res Ther; 2019 Apr; 21(1):102. PubMed ID: 30999933
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
[TBL] [Abstract][Full Text] [Related]
3. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.
Winthrop KL; Korman N; Abramovits W; Rottinghaus ST; Tan H; Gardner A; Mukwaya G; Kaur M; Valdez H
J Am Acad Dermatol; 2018 Jun; 78(6):1149-1155.e1. PubMed ID: 29080806
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).
Bingham CO; Rizzo W; Kivitz A; Hassanali A; Upmanyu R; Klearman M
Ann Rheum Dis; 2015 May; 74(5):818-22. PubMed ID: 24448345
[TBL] [Abstract][Full Text] [Related]
5. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
[No Abstract] [Full Text] [Related]
7. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
[TBL] [Abstract][Full Text] [Related]
8. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.
Migita K; Akeda Y; Akazawa M; Tohma S; Hirano F; Ideguchi H; Kozuru H; Jiuchi Y; Matsumura R; Suematsu E; Miyamura T; Mori S; Fukui T; Izumi Y; Iwanaga N; Tsutani H; Saisyo K; Yamanaka T; Ohshima S; Mori N; Matsumori A; Takahi K; Yoshizawa S; Kawabe Y; Suenaga Y; Ozawa T; Hamada N; Komiya Y; Matsui T; Furukawa H; Oishi K
Arthritis Res Ther; 2015 Dec; 17():357. PubMed ID: 26653668
[TBL] [Abstract][Full Text] [Related]
9. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
10. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L
Clin Rheumatol; 2011 Dec; 30(12):1555-61. PubMed ID: 21956234
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
[TBL] [Abstract][Full Text] [Related]
12. Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate.
Migita K; Akeda Y; Akazawa M; Tohma S; Hirano F; Ideguchi H; Matsumura R; Suematsu E; Miyamura T; Mori S; Fukui T; Izumi Y; Iwanaga N; Jiuchi Y; Kozuru H; Tsutani H; Saisyo K; Yamanaka T; Ohshima S; Mori N; Matsumori A; Kitagawa K; Takahi K; Ozawa T; Hamada N; Nakajima K; Nagai H; Tamura N; Suenaga Y; Kawabata M; Matsui T; Furukawa H; Kawakami K; Oishi K
Medicine (Baltimore); 2015 Dec; 94(52):e2184. PubMed ID: 26717361
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
14. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.
Crnkic Kapetanovic M; Saxne T; Truedsson L; Geborek P
Arthritis Res Ther; 2013 Jan; 15(1):R1. PubMed ID: 23286772
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
Fleischmann R; Takeuchi T; Schiff M; Schlichting D; Xie L; Issa M; Stoykov I; Lisse J; Martinez-Osuna P; Rooney T; Zerbini CAF
Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1112-1121. PubMed ID: 31233281
[TBL] [Abstract][Full Text] [Related]
16. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study.
Winthrop K; Vargas JI; Drescher E; Garcia C; Friedman A; Hendrickson B; Li Y; Klaff J; Kivitz A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35246470
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
